Takeda investors back $59 billion Shire deal, but wary of debt load

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.